New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 3, 2014
20:25 EDTPFE, PFE, PFE, PFE, AMGN, AMGN, AMGN, AMGN, PBYI, PBYI, PBYI, PBYI, LLY, LLY, LLY, LLY, MDVN, MDVN, MDVN, MDVN, CLDX, CLDX, CLDX, CLDXLeerink's biotech analyst holds a dinner meeting update
Biotech Analyst Liang holds an update from the AACR's Annual Meeting to discuss some of the presentations including PFE/AMGN's Palbociclib, PBYI/PFE's Neratinib, as well as other new agents for breast cancer from LLY, MDVN and CLDX, in San Diego on April 7 at 9 pm.
News For PFE;AMGN;PBYI;LLY;MDVN;CLDX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
April 21, 2015
10:01 EDTPFEPfizer receives FDA breakthrough therapy designation for Xalkori
Subscribe for More Information
08:18 EDTPFEPain Therapeutics resumes responsibility for Remoxy
Subscribe for More Information
08:06 EDTPFEPfizer says Phase 3 inotuzumab ozogamicin study met first primary endpoint
Subscribe for More Information
April 20, 2015
10:00 EDTMDVNOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:20 EDTLLYLeerink biotech analyst holds an analyst/industry conference call
Subscribe for More Information
09:01 EDTLLYEli Lilly to present early stage data from several targeted cancer therapies
Subscribe for More Information
08:17 EDTCLDXCelldex says varlilumab demonstrated synergistic anti-tumor activity with PD-1
Subscribe for More Information
08:08 EDTLLYEli Lilly announces positive results from ixekizumab study
Eli Lilly and Company announced that the investigational medicine ixekizumab was statistically superior to placebo in the treatment of patients with active psoriatic arthritis, or PsA, as demonstrated by the proportion of patients achieving an ACR 20 response. ACR 20 is a standard assessment that represents a 20% reduction in disease signs and symptoms as defined by the American College of Rheumatology response criteria. During the 24-week, Phase 3 study, titled SPIRIT-P1, patients who were naïve to biologic disease-modifying antirheumatic drugs were treated with one of two different ixekizumab dosing regimens or placebo.
08:02 EDTPFEMerck KGaA, Pfizer initiate Phase III study with Avelumab
Subscribe for More Information
07:20 EDTLLYAmerican Association for Cancer Research to hold annual meeting
Subscribe for More Information
06:35 EDTMDVNMedivation downgraded to Neutral from Outperform at Credit Suisse
Subscribe for More Information
06:05 EDTPFEProvectus receives notice of allowance for PV-10 combined with other drugs
Subscribe for More Information
April 17, 2015
09:20 EDTAMGNInsulet weakness creates buying opportunity, says Wedbush
Wedbush believes that Insulet's growth should accelerate as the year progresses, driven by increased adoption of its unique, programmable insulin pump and the launch of Amgen's (AMGN) Neulasta On-Body Delivery System.
April 16, 2015
12:16 EDTLLYEli Lilly and Bristol-Myers restructure Erbitux collaboration in N. America
Subscribe for More Information
April 15, 2015
18:56 EDTAMGNOn The Fly: After Hours Movers
Subscribe for More Information
17:06 EDTAMGNAmgen confirms FDA approval of Corlanor
Subscribe for More Information
16:40 EDTAMGNFDA approves Amgen's Corlanor to treat heart failure
Subscribe for More Information
08:04 EDTPFEPfizer: PALOMA-3 trial for IBRANCE met primary endpoint, trial stopped early
Subscribe for More Information
07:41 EDTLLYEBD Group to hold a forum
ChinaBio Partnering Forum 2015 is being held in Shanghai, China on April 15-16.
April 14, 2015
08:46 EDTPBYIPuma Biotechnology expands cohort in Phase II PB272 trial
Puma Biotechnology has expanded the second cohort from its Phase II clinical trial of its lead drug candidate PB272 as a single agent in patients with solid tumors who have an activating HER2 mutation. The cohort that has been expanded is the cohort that includes patients with metastatic non-small cell lung cancer and whose tumors have a HER2 mutation. The Phase II basket trial, which was initiated in October 2013, is an open-label, multicenter, multinational study to evaluate the safety and efficacy of PB272 administered daily to patients who have solid tumors with activating (driver) ERBB mutations, including epidermal growth factor receptor, HER2 and HER3. The cohorts (baskets) included in the study are (1) bladder/urinary tract cancer; (2) breast cancer; (3) colorectal cancer; (4) endometrial cancer; (5) gastric/esophageal cancer; (6) ovarian cancer; (7) all other solid tumors with a HER2 mutation; (8) EGFR mutated and/or amplified primary brain cancer; and (9) solid tumors with a HER3 mutation. The non-small cell lung cancer patients initially entered the study in the “other solid tumors with a HER2 mutation” basket and due to the preliminary activity seen in the trial the Company has expanded the basket, as per the protocol for the trial. The expanded HER2 mutant NSCLC basket will now enroll a total of 18 patients.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use